High levels of JAK1/2-STAT6 activation significantly affected progression-free survival STAT6 hyperactivation binds the glucocorticoid receptor (GR), which facilitates therapy resistance through ...

Of the 13 cases with a missing HER2 CISH test result (Table 2) the second staining run was not performed in four cases and, therefore, the success rate for HER2 CISH was 97.5% (352/361*100).

Source Reference: Lou E, et al "Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre ...

Ivarmacitinib, a highly selective Janus kinase 1 (JAK1) inhibitor, tamed ankylosing spondylitis with sustained efficacy through 24 weeks in a phase 2/3 trial. A phase 2/3 trial in China evaluated ...

BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune ...

Results: Of the 73 cases measured by both FISH and CISH methods, the concordance between two methods for negative and positive results was 91.7% and 97.4%, respectively, while the overall concordance ...

Exclusive global license to WEHI patent for CISH KO in the field of NK cells builds on and strengthens ONK Therapeutics’ broad intellectual property (IP) against a wide range of NK cell checkpoints ...

BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune ...